Literature DB >> 7593643

Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV.

D M Kerins1, Q Hao, D E Vaughan.   

Abstract

Recent studies from this laboratory have demonstrated that angiotensin II (Ang II) stimulates the expression of plasminogen activator inhibitor 1 (PAI-1) in cultured endothelial cells. This response does not appear to be mediated via an interaction with either the AT1 or the AT2 receptor subtype. Since a novel angiotensin receptor has been identified in a variety of tissues that specifically binds the hexapeptide Ang IV (Ang II, [3-8]), we therefore examined the effects of Ang IV on the expression of PAI-1 mRNA in bovine aortic endothelial cells. Ang IV stimulated dose- and time-dependent increases in the expression of PAI-1 mRNA. The effect of Ang IV (10 nM) was not inhibited by Dup 753 (1.0 microM), a highly specific antagonist of the AT1 receptor, or by PD123177 (1.0 microM), a highly specific antagonist of the AT2 receptor. In contrast, the AT4 receptor antagonist, WSU1291 (1.0 microM), effectively prevented PAI-1 expression. Although larger forms of angiotensin (i.e., Ang I, Ang II, and Ang III) are capable of inducing PAI-1 expression, this property is lost in the presence of converting enzyme or aminopeptidase inhibitors. These results indicate that the hexapeptide Ang IV is the form of angiotensin that stimulates endothelial expression of PAI-1. This effect appears to be mediated via the stimulation of an endothelial receptor that is specific for Ang IV.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7593643      PMCID: PMC185912          DOI: 10.1172/JCI118312

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  The angiotensin hexapeptide 3-8 fragment potently inhibits [125I]angiotensin II binding to non-AT1 or -AT2 recognition sites in bovine adrenal cortex.

Authors:  M F Jarvis; G W Gessner; C Q Ly
Journal:  Eur J Pharmacol       Date:  1992-08-25       Impact factor: 4.432

2.  Identification of an AII(3-8) [AIV] binding site in guinea pig hippocampus.

Authors:  J W Harding; V I Cook; A V Miller-Wing; J M Hanesworth; M F Sardinia; K L Hall; J W Stobb; G N Swanson; J K Coleman; J W Wright
Journal:  Brain Res       Date:  1992-06-26       Impact factor: 3.252

3.  Angiotensin degradation products mediate endothelium-dependent dilation of rabbit brain arterioles.

Authors:  R L Haberl; P J Decker; K M Einhäupl
Journal:  Circ Res       Date:  1991-06       Impact factor: 17.367

4.  Acute renal failure, tubular necrosis, and myocardial infarction induced in the rabbit by intravenous angiotensin II.

Authors:  H Gavras; A F Lever; J J Brown; R F Macadam; J I Robertson
Journal:  Lancet       Date:  1971-07-03       Impact factor: 79.321

5.  Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells.

Authors:  J A van Mourik; D A Lawrence; D J Loskutoff
Journal:  J Biol Chem       Date:  1984-12-10       Impact factor: 5.157

6.  Angiotensin II induces secretion of plasminogen activator inhibitor 1 and a tissue metalloprotease inhibitor-related protein from rat brain astrocytes.

Authors:  J A Olson; K T Shiverick; S Ogilvie; W C Buhi; M K Raizada
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

7.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

Authors:  M A Pfeffer; E Braunwald; L A Moyé; L Basta; E J Brown; T E Cuddy; B R Davis; E M Geltman; S Goldman; G C Flaker
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

8.  Inhibition of aminopeptidases by amastatin and bestatin derivatives. Effect of inhibitor structure on slow-binding processes.

Authors:  D H Rich; B J Moon; S Harbeson
Journal:  J Med Chem       Date:  1984-04       Impact factor: 7.446

9.  Identification and characterization of a new binding site for angiotensin II in mouse neuroblastoma neuro-2A cells.

Authors:  S Chaki; T Inagami
Journal:  Biochem Biophys Res Commun       Date:  1992-01-15       Impact factor: 3.575

10.  Role of aminopeptidase activity in the regulation of the pressor activity of circulating angiotensins.

Authors:  S Ahmad; P E Ward
Journal:  J Pharmacol Exp Ther       Date:  1990-02       Impact factor: 4.030

View more
  25 in total

Review 1.  The brain renin-angiotensin system: a diversity of functions and implications for CNS diseases.

Authors:  John W Wright; Joseph W Harding
Journal:  Pflugers Arch       Date:  2012-04-26       Impact factor: 3.657

2.  Identification of intracellular proteins and signaling pathways in human endothelial cells regulated by angiotensin-(1-7).

Authors:  Christian Meinert; Florian Gembardt; Ilka Böhme; Anja Tetzner; Thomas Wieland; Barry Greenberg; Thomas Walther
Journal:  J Proteomics       Date:  2015-09-24       Impact factor: 4.044

3.  Angiotensin II-mediated microvascular thrombosis.

Authors:  Elena Y Senchenkova; Janice Russell; Lidiana D Almeida-Paula; Joseph W Harding; D Neil Granger
Journal:  Hypertension       Date:  2010-10-25       Impact factor: 10.190

Review 4.  Molecular biology of angiotensin receptors and their role in human cardiovascular disease.

Authors:  V Regitz-Zagrosek; M Neuss; J Holzmeister; C Warnecke; E Fleck
Journal:  J Mol Med (Berl)       Date:  1996-05       Impact factor: 4.599

Review 5.  Now that we have a direct renin inhibitor, what should we do with it?

Authors:  Alice Stanton
Journal:  Curr Hypertens Rep       Date:  2008-06       Impact factor: 5.369

6.  Angiotensin IV enhances phosphorylation of 4EBP1 by multiple signaling events in lung endothelial cells.

Authors:  Jianghua Lu; Jianalian Zhang; Edward R Block; Jawaharlal M Patel
Journal:  Mol Cell Biochem       Date:  2005-07       Impact factor: 3.396

7.  Effect on the atherogenic marker plasminogen activator inhibitor type-1 of addition of the ACE inhibitor imidapril to angiotensin II type 1 receptor antagonist therapy in hypertensive patients with abnormal glucose metabolism: a prospective cohort study in primary care.

Authors:  Ken Yajima; Akira Shimada; Hiroshi Hirose; Yoichi Oikawa; Satoru Yamada; Shu Meguro; Junichiro Irie; Seiko Irie
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

Review 8.  Involvement of insulin-regulated aminopeptidase in the effects of the renin-angiotensin fragment angiotensin IV: a review.

Authors:  Bart Stragier; Dimitri De Bundel; Sophie Sarre; Ilse Smolders; Georges Vauquelin; Alain Dupont; Yvette Michotte; Patrick Vanderheyden
Journal:  Heart Fail Rev       Date:  2007-11-08       Impact factor: 4.214

Review 9.  [The renin-angiotensin system in cardiovascular diseases].

Authors:  C Unterberg; H Kreuzer; A B Buchwald
Journal:  Med Klin (Munich)       Date:  1998-07-15

Review 10.  Angiotensin receptor subtype mediated physiologies and behaviors: new discoveries and clinical targets.

Authors:  John W Wright; Brent J Yamamoto; Joseph W Harding
Journal:  Prog Neurobiol       Date:  2007-11-19       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.